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Post-radiation atherosclerosis and coronary artery disease (CAD), present as an increasing disease
burden in cancer survivors who have received radiation therapy. This disease is categorized as a
premature senescence-triggered vascular disease (PmSVD)1.Endothelial dysfunction in PmSVD has
been thoroughly studied, but the lack of available treatments to prevent cardiovascular complications
should be remedied2, 3.
Extracellular signal-regulated kinase 5 (ERK5/BMK1/MAPK7), has been shown to inhibit shear stressinduced anti-inflammatory effects in endothelial cells4. p90RSK activation is associated with
endothelial cell inflammation and atherosclerosis. PCK-ζ is a redox-sensitive kinase that directly
associates with TOP2β and inhibits its activity5. TOP2β protects against telomeric dysfunction.
Additionally, Poly(ADP-ribose)/PARP synthetase activation-induced NAD+ depletion increases the MtNucleus positive feedback loop.
The point of our experiment was to clarify whether premature senescence-induced phenotype (PISP)
in post-chemotherapy cells could be inhibited by eliminating sources of mitochondrial damage with
metabolite inhibitors (PARP inhibitor/Olaparib, SGLT2 inhibitor, and colchicine.)

Role of Colchicine, SGLT2 inhibitors and Olaparib in inhibiting PISP

Materials/Methods

Introduction

Cell Culture: Hela cells were cultivated until 80~100% confluency from frozen stocks in
DMEM, penicillin-streptomycin, and 10% FBS. The cells were then passaged into 6-cm plates
equally, and cultured until 90~100% confluence. The cells were pre-treated with Olaparib (10μM),
Colchicine (10 nM), or the SGLT2 inhibitor dapagliflozin (10μM). 1 hour after pre-treatment, the cells
were treated with Doxorubicin at 10 μM for 24 hours, and were then lysed with RIPA+ buffer with
phosphatase inhibitors to collect protein. The protein lysates were spun down at 7000 RPM for 10
minutes at 4°C to isolate the protein lysate. The lysates were then transferred to a different
Eppendorf tube and stored at -80°C until quantification.
Western Blotting: Protein quantified using the BCA Assay and BSA standards. The samples were
loaded at 30ug/well and then run on a 10% SDS-PAGE gel. The blot was then transferred at 90V for
1 hour to a nitrocellulose membrane, blocked in 5% powdered milk in TBST, and then probed with
antibodies to p-p90RSK, p-PKCζ, and p-ERK4-S496 at a concentration of 1:1000, 1:3000, and
1:1000 respectively. The blots were then washed for 30 minutes with TBST, incubated in goatproduced anti-mouse IgH, at a concentration of 1:3000 and then imaged on the chemiluminescence
machine.
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Histology: LDLR -/- mice were fed a high-fat diet for 2 weeks, exposed to localized IR (5gy) in the
neck and thoracic area twice. Mice were then fed a normal diet until their weight recovered, and
HFD was restarted for ~2 weeks. Thoracic aorta coarctation (TAC) was then performed at ~4 weeks
later, echocardiography was performed and samples were harvested from mice after euthanization.
Hematoxylin + eosin staining 4 weeks after TAC at different distances from the aortic valve to the tip
of the heart were performed, as well as quantification of stenosis grades. Fractional shortening was
also measured.

Late phase of colchicine treatment inhibited monocyte priming, ATP/NAD+ depletion
and inflammation after IR in vivo.
C57Bl6 mice were exposed to localized. IR (5Gy x2) in the neck
and thoracic area (5 Gy). A low dose of colchicine treatment
was started after 2 weeks of IR, and continued for 2 weeks.
Bone Marrow Derived Macrophages were isolated from the
femurs and tibias of mice, which were not exposed to ionizing
radiation. (B) p90RSK in circulating monocytes leads to
prolonged inflammation and atherosclerosis. Activation leads to
radiation-induced inflammation by establishing Mt-nucleus
positive feedback loops containing mitochondrial reactive
oxygen species production, telomere damage and NAD+
depletion. p90RSK activity in CD11b+ (mouse monocyte) cells
was detected by flow cytometry. The data was obtained from
total 5-6 mice. (C) ATP and NAD+ levels were detected from
BMDMs isolated from mice treated as shown in (A). Significant
long-lasting decrease of ATP and NAD+ levels in cultured
BMDMs isolated from tibia and femurs, which were not directly
exposed to ionizing radiation, even after 30 days of radiation.

Results

We have shown that PARP inhibitors can reduce IR-induced coronary atherosclerosis and myocardial
infarction. Additionally, SGLT2 inhibitors such as dapagliflozin have been shown in improve cardiovascular
outcomes such as heart failure, mortality, and metabolic outcomes in patients with type 2 diabetes (T2DM) at high
cardiovascular risk 6, 7, 8. This drug has also been shown to prevent high-fat, high-sucrose-induced pathological
cardiac remodeling, improved contractile reserve and increased expression of oxidative phosphorylation and fatty
acid metabolism independent of diabetes status in mice 9. SGLT2 inhibitors have also been shown to attenuate
inflammation and promote fat utilization as well as insulin resistance in obese mice by polarizing M2
macrophages10. Colchicine has anti-inflammatory and anti-coagulant properties, and the COLCOT (Colchicine CV
outcome trial study), Colchicine reduced the risk of ischemic CV events11.

Directions for future study/comments
We will test other inhibitors (HA inhibitors such as 4-MU, PG545, NMDAR inhibitors such as MK-801,
memantine, NAD+ precursors such as NR, MAD+, H2S donors such as DATS, NaHS, BH4 precursors such as
Sepiapterin) to see if they are protective against mitochondrial reactive oxygen species and telomeric DNA damage
and dysfunction triggered by cancer treatments such as irradiation, cardiotoxic drugs such as doxorubicin, and
immune checkpoint inhibitors to potentially find prophylactic treatments for post-chemotherapeutic atherosclerotic
disease. These inhibitors may be able to inhibit the Mt-nucleus positive feedback loop and protect against
mitochondrial damage.

Summary
Certain treatments for cancer (IR, ICI, and doxorubicin) cause
comorbidities such as PmSVD. We want to try and find medications
that will protect against these complications, such as agents that
will protect against mitochondrial and inflammatory damage due to
ROS.

P-PKCζ
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We are looking at the role of p-PKCζ in cancer cells. We wanted to see whether Olaparib (PARP
inhibitor) would inhibit phosphorylation of PKCζ or increase it. After 24 hours of treatment with
Doxorubicin after 1 hour of inhibitor treatment, we observed an increase PKCζ phosphorylation in
Hela cells treated with doxorubicin, indicating the presence of chemotherapeutic mtDNA damage.
The band of Hela cells treated with doxorubicin for 10 and 30 minutes shows slightly more
phosphorylation at 30 min vs 10 min. The same trend is true in Hela cells treated with Doxorubicin
after 10 and 30 minutes. However, Olaparib induction for 1 hour and doxorubicin treatment for 24
hours shows significant reduction in P-PKCζ, indicating that Olaparib inhibits phosphorylation of
PKCζ. These results indicate that by Olaparib may be able to act prophylactically against
chemotherapy-induced cardiotoxicity.
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Discussion
Acknowledgements
Seen inhibition of phosphorylation of PKCζ in HeLa cells treated with doxorubicin after 1 hour of
stimulation with Olaparib. This indicates that Olaparib has therapeutic potential in reducing postchemotherapeutic atherosclerosis. This experiment must be repeated 2 more times and re-run with
other inhibitors (SGLT2, Colchicine).
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